The immunosuppressant drug cyclosporin A is widely used to prevent organ rejection in recipients of renal, liver and heart transplants. In lower doses it has been used to treat a variety of skin diseases', particularly psoriasisv". We have recently treated two patients with cyclosporin A for their severe atopic eczema with encouraging early results.
Case reports
Case 1: This 30-year-old man had asthma, hay fever and atopic eczema in childhood. His eczema had persisted since then, apart from a brief remission in his early teens. Between November 1983 and January 1986 he has required 6 admissions to hospital for flares of eczema, particularly after sun exposure and usually complicated by secondary bacterial infection. Investigations during this period showed serum IgE> 1000 U ml " and negative patch tests.
Because of the resistant nature of his eczema, psoralens and ultraviolet A (PUVA) therapy was tried with a good response for a period of 4 months, until work commitments prevented his attendance. Azathioprine was substituted in a dose of 50 mg twice daily. He developed a macular erythematous rash, peripheral oedema, arthropathy and lymphadenopathy which were interpreted as an adverse reaction to the azathioprine. This was therefore stopped. At this stage he lost his job because of absenteeism through this ill-health. A further course of PUVA led to an erythrodermic flare of the eczema, at which time monochromator light tests showed abnormal photosensitivity with reduced minimum erythema doses in the ultraviolet A and B (307.5-360 nm). Oral steroids were commenced but were unable to control the disease except in high doses. Atopic keratoconjunctivitis was diagnosed at this stage, and the systemic steroids were stopped. Rectal bleeding developed due to rectal prolapse with a solitary rectal ulcer -this has subsequently been repaired surgically and histological examination of the ulcer showed no malignancy.
As a last resort to control the eczema oral cyclosporin A was commenced in March 1986 at a daily dose of 200 mg (2 mg kg"), Within 3 days the eczema was dramatically improved. It has remained under control during the ensuing 11 months using doses of cyclosporin ranging from 2 to 4 mg kg? a day, in combination with topical steroids, a topical antibiotic and oral antihistamines. The eczema has flared within 3 days when cyclosporin was stopped and also when the daily dose was reduced below 1 mg kgr". The patient is now back in full-time employment.
No haematological or renal side effects have been detected. Liver function tests have shown a rise in alanine aminotransferase from 30 U 1-1 pretreatment to 51 U I-I (normal range < 20)_ This was thought to be due to sodium cromoglycate therapy, and the levels returned to pretreatment values when this drug was stopped. Trough levels of cyclosporin A (measured in whole blood by radioimmunoassay) have ranged between 190 and 509/lg1-1.
Case 2: A 60-year-old man with a past history of bronchial asthma, developed endogenous eczema at the age of 40. Therapy with topical steroids was successful until the age of 58 when he developed a flare of eczema on exposed sites in the summer months. This progressed to erythroderma requiring hospital admission. Investigation revealed: numerous positive skin prick tests to common antigens; serum IgE> 1000 U ml": 'angry back' on patch testing; negative photopatch tests; no circulating Sezary cells; monochromator light tests demonstrated abnormal papular reactions in the ultraviolet B range (300-320 nm), but normal minimal erythema doses.
The eczema failed to settle with topical therapy but was eventually controlled by oral photochemotherapy (PUVA) for a period of 6 months, at which stage PUV A was stopped. Three months later the eczema again relapsed, PUVA was restarted but precipitated erythroderma requiring readmission to hospital. Because of very slow progress he was started on oral prednisolone 60 mg a day. The eczema settled, but when the oral steroid was tailed off following dyspepsia a further erythrodermic relapse occurred requiring admission. A course of azathioprine 150 mg daily for 3 months produced no improvement.
Oral cyclosporin A was therefore commenced at a dose of 240 mg daily (4 mg kg-I). The skin settled within 2 weeks as an inpatient on this dose. Subsequently the dose had to be increased to 300 mg daily (5 mg kg-I) to keep control of the eczema as an outpatient. Regular and extensive screening for side effects has revealed a slight rise in blood pressure from 130/80 to 135/95. This is thought to be due to a peripheral vasoconstrictor effect as there has been no evidence of deterioration in renal function, nor any change in peripheral blood count. A pre-existing, mild and asymptomatic elevation of alkaline phosphatase has not deteriorated. Trough levels ofcyclosporin have gradually risen from 242 to 572/lg1-1, at which stage the dose of cyclosporin was reduced to 240 mg daily.
The patient's eczema has now been controlled for 5 months on oral cyclosporin A.
Discussion
Cyclosporin A therapy has been associated with a most satisfactory and sustained improvement in these two cases of severe atopic eczema for which other treatments had failed. The length of remission in both patients and the rapid relapse of disease on withdrawal of cyclosporin A in one patient suggest that the improvement is drug related and not coincidental. This possibility is supported by another recent report of two patients whose atopic eczema improved with cyclosporin A4. However enthusiasm for the use of this drug in the treatment of atopic eczema must be tempered by the risk of serious sideeffects, particularly nephrotoxicity.
Studies in mice have shown that cyclosporin can suppress spontaneous IgE formation via a T-cell dependent mechanism", This may be a mode of action in atopic eczema, but the exact mechanism and role of cyclosporin A in the management of severe atopic eczema await further study. Of all squamous cell carcinomas, 1-2% arise on the foot where they are usually plantar in site and exophytic in appearance. Occurrence on a toe is exceptional. Two cases of squamous cell carcinoma of the toe of differing origins, and masquerading both clinically and radiologically as osteomyelitis, are reported.
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Case reports
Case 1: A 54-year-old postman sustained a stub injury to his right hallux after falling off his bicycle, resulting in nail avulsion. Local inflammation was present, unresponsive to two courses of antibiotics. On referral to the local Accident and Emergency Department, osteomyelitis of the distal phalanx was diagnosed as a result of persistent pain, inflammation and radiological evidence of osteolysis of the distal phalanx. The deformed regenerated nail was avulsed and culture of the nail bed grew Aspergillus, Candida and diphtheroids. Treatment with systemic fusidic acid was commenced, but increasing pain, a fluctuating bulbous deformity of the hallux and an associated progressive osteolysis on repeat X-ray ( Figure 1 ) 6 weeks later, led to
